Unsupervised medical abortion with misoprostol among adolescent—what is the prospect of demedicalise abortion in sub-Saharan Africa?
Adebiyi Gbadebo Adesiyun, Austin Ojabo
DOI: 10.4236/ojog.2011.14046   PDF    HTML     4,201 Downloads   7,548 Views  


Objective: To find out clinical presentation and outcome of unsupervised use of misoprostol as abortifacent among adolescents presenting with abortion complications. Methods: Case series of thirty one adolescents that presented with abortion complications following unsupervised use of misoprostol. Results: Over a period of 3 years, 31 adolescents were seen, with median age of 17 years. Twenty nine (93.5%) were unmarried and 22 (71%) were in secondary school. Pregnancy duration was 3months and above in 23 (74.2%) of the patients. The cumulative dose of misoprostol tablet ingested was 2 (400 µg) in 17 (54.8%) of the patients. Twenty three (74.2%) patients presented with incomplete abortion with mild sepsis while the remaining 8 (25.8%) patients were admitted and managed with incomplete abortion with severe sepsis. Treatments offered were manual vacuum aspiration in 23 (74.2%) patients, evacuation of retained product of conception under anaesthesia in 7 (22.6%) patients and 1 (3.2%) patient had laparotomy with uterine repair following inadvertent uterine perforation complicating curettage for incomplete abortion. Complications encountered were anaemia 67.7%, uterine perforation 3.2%, blood transfusion 9.7% and diarrhoea in 8 (25.8%) patients. Conclusion: Demedicalise abortion with misoprostol due to improper dosing protocol may be associated with incomplete abortion and its sequelae in an uninformed adolescent population. Establishment of adolescent friendly medical centre that offers post abortion care will go a long way in alleviating this problem.

Share and Cite:

Adesiyun, A. and Ojabo, A. (2011) Unsupervised medical abortion with misoprostol among adolescent—what is the prospect of demedicalise abortion in sub-Saharan Africa?. Open Journal of Obstetrics and Gynecology, 1, 235-238. doi: 10.4236/ojog.2011.14046.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] The Alan Guttmacher Institute (1998) Into a new world —young women’s sexual and reproductive lives: Young women in a changing world. New York, 5-9.
[2] Treffers, P.E., Olukoya, A.A., Ferguson, B.J. and Liljestrand, J. (2001) Care for adolescent pregnancy and childbirth. International Journal of Gynecology & Obstetrics, 75, 111-121. doi:10.1016/S0020-7292(01)00368-X
[3] Okonofua, F.E. (2004) Editorial: Breaking the silence on prevention of unsafe abortion in Africa. African Journal of Reproductive Health, 8, 7-8. doi:10.2307/3583174
[4] Population Council (2001) Misoprostol: An emerging technology for women’s health, report of a seminar. Shannon, C.S. and Winikoff, B., Eds., New York, 2.
[5] Ellertson, C., Elul, B. and Winikoff, B. (1997) Can women use medical abortion without medical supervision? Reproductive health matters, 9, 149-161. doi:10.1016/S0968-8080(97)90019-7
[6] Elul, B. (1998) Medical methods of early abortion in developing countries. Consensus statement, Contraception, 58, 257-259. doi:10.1016/S0010-7824(98)00109-7
[7] Winikoff, B., Siviel, Coyaji, K.J., et al. (1997) Safety efficacy and acceptability of medical abortion in China, Cuba and India: A comparative trial of mifepristone—misoprostol versus surgical abortion. American Journal of Obstetrics & Gynecology, 176, 431-437. doi:10.1016/S0002-9378(97)70511-8
[8] Carabonell, J.L., Velazco, A., Varela, L., Tanda, R., Sanchez, C., Barambio, S., Chami, S., Valero, F.-A., Sanchez, S. and Mari, J. (2001) Misoprostol for abortion at 9 weeks - 12 weeks gestation in adolescents. European Journal of Contraception and Reproductive Healthcare, 6, 39-45. doi:10.1080/13625180008500367
[9] Carabonell, J.L., Varela, L., Velazco, A., Tanda, R., Barambio, S. and Chami, S. (2000) Vaginal misoprostol 600 microgram for early abortion. European Journal of Contraception and Reproductive Healthcare, 5, 46-51
[10] Herabutya, Y., Chanrachakul, B. and Punyavachira, P. (2001) Second trimester pregnancy termination: A comparison of 600 and 800 micrograms of intravaginal misoprostol. Journal of Obstetrics and Gynaecological Research, 27, 125-128. doi:10.1111/j.1447-0756.2001.tb01235.x
[11] Wong, K.S., Ngai, C.S., Yeo, E.L., Tang, L.C. and Ho, P.C. (2000) A comparism of two regimens of intravaginal misoporstol for termination of second trimester pregnancy: A randomized comparative trial. Human Reproduction, 15, 709-712. doi:10.1093/humrep/15.3.709
[12] Rabe, T., Basse, H., Thuro, H., Kiesel, L. and Runnebaum, B. (1987) Effect of the PGE1 methyl analog misoprostol on the pregnant uterus in the first trimester. Geburtshilfe Frauenheilkd, 47, 324-331. doi:10.1055/s-2008-1035830
[13] Norman, J.E., Thong, K.J. and Baird, D.T. (1991) Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet, 338, 1233-1236. doi:10.1016/0140-6736(91)92102-8
[14] Carabonell, J.L., Varela, L., Velazco, A. and Fernandez, C. (1997) The use of misoprostol for early termination of pregnancy. Contraception, 55, 165-168. doi:10.1016/S0010-7824(97)00020-6
[15] Carabonell, J.L., Varela, L., Velazco, A., Fernandez, C. and Sanchez, C. (1997) The use of misoprostol for abortion at < or = 9 weeks gestation. European Journal of Contraception and Reproductive Healthcare, 2, 181-185.
[16] Adjase, E.T. (2004) Misoprostol, an emerging technology for women’s health, report of a seminar. Shannon, C.S. and Winikoff, B., Eds., Population Council, New York, 200, 5-12.
[17] World Health Organization (1994) Abortion: A tabulation of available data on the frequency and mortality of unsafe abortion. 2nd Edition, Geneva, Switzerland.
[18] Ibrahim, S.A., Iliyasu, Z. and Musa, J. (2006) Maternal mortality in Jos University Teaching Hospital, Nigeria. Trop Journal of Obstetrics and Gynaecology, 23, 152-155.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.